Drug discovery: new models for industry-academic partnerships

Drug Discovery Today

Volumn 14, Issue 1-2, 2009, Pages 95-101

  Tralau Stewart, Cathy J ^a   Wyatt, Colin A ^a   Kleyn, Dominique E ^a   Ayad, Alex ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMBINATORIAL CHEMISTRY; COMMERCIAL PHENOMENA; COST; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG RESEARCH; FUNDING; HIGH THROUGHPUT SCREENING; PRODUCTIVITY; PUBLIC PRIVATE PARTNERSHIP; REVIEW; UNITED KINGDOM;

ANIMALS; COOPERATIVE BEHAVIOR; DRUG DISCOVERY; DRUG INDUSTRY; FINANCING, GOVERNMENT; HUMANS; MODELS, ORGANIZATIONAL; RESEARCH SUPPORT AS TOPIC; UNIVERSITIES;

EID: 58149141541     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.10.003     Document Type: Review

References (33)

1. DiMasi J.A., et al. The price of innovation: new estimates of drug development costs. J. Health Econ. 22 (2003) 151-185
2. Brewer G.J. Fundamental problems lie ahead in the drug discovery and commercial process: restructuring of the pharmaceutical industry and an improved partnership with academia are required. J. Invest. Med. 54 (2006) 291-302
3. Branca MA. Academia given a helping hand in drug development. Nat. Rev. Drug Discov. 5 (2006(March)) 177
4. Chan P. How can the pharma industry recapture its innovative edge?. SCRIP NEWS (2008) 1-7
5. Booth B., and Zemmel R. Prospects for productivity. Nat. Rev. Drug Discov. 3 (2004) 451
6. Subramaniam S. Productivity and attrition: key challenges for biotech and pharma. Drug Discov. Today 8 (2003) 513-515
7. Datamonitor (2007) The key trends and strategic issues shaping the Industry. Reference Code DMHC2272 02/2007
8. White Paper (2006) Our health, our care, our say. Presented to Parliament by the Secretary of State for Health January 2006 (http://www.dh.gov.uk)
9. Cuatrecasas P. Drug discovery in jeopardy. J. Clin. Invest. 116 (2006) 2837-2842
10. Garnier J.P. Rebuilding the R&D engine in Big Pharma. Harvard Business Rev. (2008)
11. Drews J. Strategic trends in the drug industry. Drug Discov. Today 8 (2003) 411-420
12. Gudiksen M., et al. What drives success for specialty pharmaceuticals?. Nat. Rev. Drug Discov. Advance Online Publication (2008) 10.1038/nrd2594
13. Pharmatimes (2008) GSK cuts 2% of its research staff as restucturing moves ahead. (http://www.pharmatimes.com/worldnews/articles.aspx?id=13688&src=EWorldNews)
14. ABPI (2006) Developing world medicines. Briefing paper reference 568/06/6600x(http://www.abpi.org.uk/)
15. Nwaka S., and Ridley R.G. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat. Rev. Drug Discov. 2 (2003) 919-928
16. Kleyn D., et al. Partnership and Innovation in the Life Sciences. Int. J. Innovation Management 11 (2007) 323-347
17. Sykes, R (2007) University Funding-Mixing business and academia 'hard to do' Financial Times Interview Tuesday 30th October 2007
18. Observer (2007) Innovation at Imperial College. Sunday December 9, 2007(http://www.guardian.co.uk/theguardian/2007/dec/09/obsextra3.observerspecial5)
19. Davis, C (2003) Imperial mint maker. Times Higher Education 28th March 2003(http://www.timeshighereducation.co.uk/story.asp?storyCode=175624§ioncode=26)
20. Hall Z.W., and Scott C. Editorial: university-industry partnership. Science 291 (2001) 553
21. Kozlowski R.Z. Industrial-academic collaboration: a bridge too far?. Drug Discov. Today 4 (1999) 487-489
22. Feldman M., and Maini R. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nature Med. 9 (2003) 1245-1250
23. Newell H (2008) CR-UK BACR Cancer therapeutics conference. Cambridge 7-9th September
24. FitzGerald G.A. Drugs, industry, and academia. Science 320 (2008) 1563
25. Clery D. U K's Royal Society ventures into funding start-up companies. Science 319 (2008) 1473
26. The Drug Discovery Process in Academia BioForum Europe 6/2008(http://corporate.gitverlag.com/media/blaetterkatalog/bfe/2008-06/index.html)
27. Rudy A.P., et al. Universities in the age of corporate science: The UC Berkely-Novartis Controversy (2007), Temple University Press
28. Gambardella, A. L. et al. (2000) Global competitiveness in pharmaceuticals-a European perspective. Report prepared for the Enterprise Directorate-General of the European Commission
29. Vallence P. Biotechnology and new companies arising from academia. Lancet 358 (2001) 1804-1806
30. Lench, N. (2007) A meeting of minds: working with academia. Pharmafocus 20-21st October
31. McKinnon, R. et al (2004) Crisis? What Crisis? A Fresh Diagnosis of Big Pharma's R&D Productivity Crunch. Research paper from Marakon Associates(http://www.marakon.com/ideas_pdf/id_041104_mckinnon.pdf)
32. Wilgenbus K., et al. What pharma wants. Nature Biotechnol. 25 (2007) 967-969
33. Association of The British Pharmaceutical Industry, Facts and Statistics from the pharmaceutical industrylist, http://www.abpi.org.uk/statistics/section.asp?sect=2.